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Background/aim: Calcineurin, an inhibitor of calcium dependent phosphatase is highly presented in a brain of an Alzheimer’s disease.
Aging brain gets more sensitive to hyperactivation of calcineurin, and this event causes tau neurofibrillary plaque accumulation, which
is one of the outcomes of this disease. The regions of hippocampus are much effected from the results of this process. Our hypothesis
is that a calcineurin inhibitor, tacrolimus, could prevent the accumulation and the decrease of the neuronal cells. Therefore, this
immunosuppressive drug could be a candidate for an early treatment of Alzheimer disease.
Materials and methods: Fifteen male Wistar albino rats were divided to three groups; control, Alzheimer, and Alzheimer+Tacrolimus.
The Alzheimer group received an injection of streptozotocin intracerebroventricularly for the purpose of modelling the disease via
generating free radicals leading a cognitive impairment. Alzheimer+Tacrolimus group first received an oral drug, a calcineurin inhibitor
for 10 days afterwards prepared for the model as same as the Alzheimer group received. Finally, all groups performed the Morris water
maze test for four days then sacrificed. For the aim of counting neurons in the hippocampus stereological methods, as well as for an
evaluation of cellular response to stress in dentate gyrus, a c-Fos immunohistochemistry was performed.
Results: According to the probe trial of Morris water maze test, the latency time was dramatically higher at both Alzheimer and
Alzheimer+Tacrolimus group (p < 0.01). We confirmed these results with our stereology data. The results from stereology technique
indicate that there was a neuronal decrease at the hippocampus regions in Alzheimer and Alzheimer+Tacrolimus group. Our outcomes
from immunohistochemical data showed a significant increase in the number of c-Fos-positive cells in Alzheimer group when comparing
with Alzheimer+Tacrolimus group (p < 0.001).
Conclusion: There was none preventive effect for neuronal loss in the hippocampus under the effect of tacrolimus drug according to
stereological results. However, tacrolimus administration may have reduced cellular stress and cell damage.
Key words: Alzheimer’s disease, c-Fos, Morris water maze test, stereology, tacrolimus

1. Introduction
Alzheimer’s disease (AD), the most common dementia
in older population is a progressive neurodegenerative
age-related disease. The frequency of this disease is 0.1%
between 60 and 65 ages and increases logarithmically up
to 48% over age of 85. Considering that, by 2050, 25%
of the world’s population will be over 65; AD will be the
most important health problem on the top [1]. There is no
promising cure yet in fact the main factor that lies under
the mechanism to cause the defects is not even known
for certain. However, we know that the most important
defect of this disease is the debates which appears as a
form of amyloid beta (Aβ) plaque accumulation [2]. These
plaques later become a slayer for the neuron itself. It is

not accurate to label the pathway either as apoptosis or as
necrosis, which is another fact to discuss [3]. However, it is
certain that significant amount of neuron dies through this
process. Another known defect is the tau neurofibrillary
tangles, which occur between the neurons and in later
on interrupts the communication between each of them.
Without communication and nutrition, neurons begin to
die and soon cell reduction happens. As time progresses
more the Aβ plaques accumulate more debits surrounds
the brain. Patients usually die of aspiration pneumonia
about 9 years after disease onset [4].
Different drugs are used for AD treatment, but they
can only slow the decline of the diseases’ progression. A
class of a pharmacotherapy which contains cholinesterase
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inhibitors such as Tacrine, Rivastigmine, and Galantamine
are used for AD treatment nowadays [5]. According to
the amyloid cascade hypothesis, a mutation in the genes
plays a role in amyloid processing. This mutation causes
an imbalance between the production of amyloid and
the clearance. Eventually, amyloid depositions appear
and these depositions induce amyloid plaques and also
neurofibrillary tangles [6]. During aging, calcium (Ca2+)
dependent protein phosphatase calcineurin (CaN)
increases in the hippocampus. CaN which also have known
as protein phosphatase 2B (PP2B) is a Ca2+ sensitive
serine/threonine phosphatase. CaN is a heteromeric
protein, which contains two subunits. These subunits are
a catalytic subunit and a regulatory subunit (CaNB) [7].
CaN is activated by calmodulin (CAM). By the activation
of CaN by CAM, CaN get responsive to some ion channel
types causing Ca2+ fluctuation in the brain. Eventually,
this distribution can cause several pathogenesis outcomes
including tau hyperphosphorylation, synaptic protein loss,
neuroinflammation, decreased neurotransmission levels,
and cell death [8].
Tacrolimus (FK506) is an immunosuppressive agent
constantly used for treating graft rejection in organ
transplantation and also for treating myasthenia gravis,
arthritis, and atopic dermatitis. As the FK506 binds to
FK506-binding protein (FKBP) a complex FK506/FKBP
interacts and inhibits CaN’s effects [9–11]. There are some
studies using tacrolimus for its effect on neurological
disease. For example, Pardo et al. [12] reported a study
about an administration of FK506 to Huntington’s disease
(HD) model mice. They found that administration
of FK506 may be successful in order to induce the
phosphorylation of S421 and block polyQ-huntingtininduced neuronal death. CaN can be a potential use as
a therapeutic approach to treat HD. A 5-year follow-up
study report based on seronegative myasthenia gravis, a
disease occurs in an absence of a seropositive status for
anti-acetylcholine receptor (AChR) antibodies, describes a
case of juvenile triple-seronegative myasthenia gravis that
was successfully managed with tacrolimus therapy [13].
Briefly, tacrolimus is widely used in organ transplantation
and autoimmune diseases such as myasthenia gravis,
inflammatory myopathy, ulcerative colitis, and lupus
nephritis [14].
In the present study, after an intracerebral ventricular
injection of streptozotocin (STZ) (3 mg/kg) on the right
brain hemisphere we waited for 14 days to modulate
an AD model organization for both Alzheimer and
Alzheimer+Tacrolimus group. An immunosuppressive
drug Prograf (tacrolimus active ingredient) has given
as an oral formulation, suspended in water. Agent was
administered orally via gavage at a volume of 0.5 mg/kg
per day to the subjects. For demonstrating, the memory
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spatial behavioral Morris water maze (MWM) test,
immunohistochemical analyses, and stereology technique
were applied for all three groups.
2. Materials and methods
2.1. Designing the groups
This study was approved by Ondokuz Mayıs University
Animal Ethics Committee (No. 2015/05-f-12 dated
20.01.2015). All animals obtained from Ondokuz Mayıs
University, Research Center for Experimental Animals
(DEHAM). A total of 15 male Wistar albino rats (250–300
g) at the age of 8–12 weeks were divided into 3 equal groups
as control, Alzheimer, and Alzheimer+Tacrolimus. Rats
were kept in standard plastic cages in an air-conditioned
room at 22 ± 1 °C under lighting controls (14-h-light/10h-dark cycle). At the control group, neither surgery nor
drug administration was done. The Alzheimer group was
consisting of ICV injection of a single STZ dose (3 mg/
kg) at the right side of the brain hemisphere including rats
for attempting to be an AD model organization [15]. In
Alzheimer+Tacrolimus group, the rats received daily 0.5
mg/kg tacrolimus (FK506, Prograf, Astellas Pharmas, US,
Inc.) diluted in tap water (0.2 ml) starting 10 days prior
to the STZ injection surgery. All groups performed the
memory spatial behavioral MWM (Morris water maze)
test at the same time and under same conditions.
2.2. Intracerebral ventricular injection of STZ
STZ (Sigma-Aldrich, S0130 - 50 MG, Inc., City name?,
Germany) was administered once into the intracerebral
ventricular representing by a following rat atlas coordinates
from the bregma (posterior, lateral, z axis): 0.8 mm, 1.5
mm, 3.6 mm, respectively [16]. Each 1 μL injection given
with Hamilton syringe was administered over 2 min at a
concentration of 3 mg/kg STZ dissolved in 5 μL citrate
buffer (pH: 4.0; 0.05 M) at room temperature. According
to the literature, we waited 14 days for the formation of AD
rat model organization considering the surgery day as first
day [17,18].
2.3. Stereology technique application
The brain samples were removed from each animal after
the standard perfusion protocol
using saline and 4% formaldehyde via the vascular
system. The obtained samples were kept 10 days in 10%
formaldehyde for fixation, and then tissue processing steps
were performed. After following the steps, the samples were
embedded in paraffin blocks, and sections were obtained
with the thickness of 7 microns (µ) with a 1 / 7 sampling
using a microtome (Leica RT 2255, Germany, Nussloch)
and finally were stained with Cresyl violet dye (Figure
1). The cross-sectional areas were sampled and imaged
using an Olympus BX43F (Japan, Tokyo) microscope and
physical dissector method was applied.
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Figure 1. Coronal sections obtained from hippocampus stained with Cresyl violet are seen in this figure. All of the groups represent their
own CA1, CA2, CA3 regions. Scale bar represents 40 μm.

‘Stereology entails statistical sampling principles and
stochastic geometric theory to provide efficient tools for
estimation of volume, surface area, length, and number
of objects in a 3-D structure by sampling in 2-D sections’
[19]. Physical dissector method is one of the stereology
methods allowing researchers to count the cells in certain
areas using an unbiased counting frame. The counts
obtained from the sections are the object density (Nv). We
reached the reference volume as a result of multiplying the
area calculations made by the computer with the section
thickness. The total cell number (N) was obtained as a
result of multiplying the object density and the reference
volume (Vref). The formula was as given as; N = Nv ×
Vref [20]. These results gave us quantitative information
about the whole structure of the related hippocampus
neuron cell amount. Here we used the physical dissector
in conjunction with Cresyl violet staining to estimate the
neuronal cell numbers situated in CA1, CA2, CA3 and

dentate gyrus (DG) regions of the rat hippocampus to
discover the changes in mean neuron number. Statistical
signification was determined by one-way analysis of
variance followed by ANOVA comparison test.
2.4. Immunohistochemical detection of c-Fos in DG
region
C-Fos belongs to a family of transcription factors and
undergoes posttranslational modifications, plays an
important role in cell proliferation, differentiation, and
it is required for memory recall and encoding [21]. It is
involved in cellular responses to stress, cell damage and
death; it is also induced in stress, mitogenic growth factors,
cytokines and neurotransmitters. C-Fos expression were
found in the spinal cord, dorsal root ganglion, in brain
areas, and finally association between the spinal cord and
brain areas [22]. In our study, immunohistochemistry was
performed for evaluation of c-Fos-positive cells in the DG
of the hippocampus according to a described method.
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While the sections were obtained from the samples, at the
same time, 5 µm slices were obtained from each animal for
immunohistochemical analyses in poly-lysine glass slides.
After the deparaffinization and rehydration processes, the
staining was performed using HRP/AEC detection IHC
kit specific for rabbit and mouse (Abcam, UK). All steps
were performed according to manufacturer’s instructions.
Prior to immunostaining, sections were incubated at
650W for 10 min in citrate buffer (pH = 6.0) for epitope
recovery. Subsequently, immunohistochemical staining
was performed using primary mouse monoclonal antibody
specific to rabbit anti c-Fos (Abcam) diluted 1:500 in
antibody diluent (specimens were incubated overnight
at 4 °C). The sections were washed three times for 2 min.
with phosphate buffer (pH = 7.4) and incubated with a
peroxidase labeled dextran polymer conjugated to goat
anti-mouse and anti-rabbit immunoglobulins at room
temperature. Color was developed using a liquid 3-Amino9-ethylcarbazole (AEC) system. Mayer’s hematoxylin was
used as a counterstain, and Kaiser’s glycerol gelatin (Merck
AG) was used for mounting coverslips. The stained sections
were analyzed by the light microscopy. The tissues were
examined for antibody attachment to cellular and matrix
components. The numbers of c-Fos-positive cells in DG
of the hippocampus were counted hemi-laterally using a
light microscope (Leica Microsystems GmbH, Wetzlar,
Germany) and the results were expressed as the number of
cells per square millimeter (mm2).
2.5. MWM test for hippocampal dependent learning
The MWM test is used for many years in the field of
neuroscience, developed by Richard G. Morris in 1981
for behavioral neuroscience [23]. This experiment
gives researchers an evidence about the subjects’ spatial
memory beside long term spatial memory when studying
neurocognitive diseases such as AD and traumatic brain
injuries [24]. There are several ways to study this method
such as monitoring the environment with a camera and also
measuring the period at the same time or using technical
apparatus for obtaining prepared data conclusions for
example coordinates. Animals are placed in a pool filled
with tap water and colored with white powder to form the
opaque view so that they cannot be able to see the platform.
The animal’s mission is to find the hidden platform with
the skills that they have learned from the previous test
(pretests). If the animal has have learned it will be able to
find the platform quickly as possible. The numerical value is
going to be the record of the latency time which the animals
will spend to find the hidden platform in the pool. At our
study, we used a camera and a timer for recording the
latency time and we wrote down the results for each animal.
2.6. Statistical analysis
The normality test was determined by Kolmogorov–Smirnov
test (p < 0.05). The mean ± standard deviation value was
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used for variables suitable for normal distribution. The
presented data were tested for significance in repeated
measures of one-way ANOVA, using the Tukey’s test (post
hoc test) for multiple comparisons. The t test was used if
the distribution of the variable was normal; otherwise,
Mann–Whitney U test was performed. Significant results
were marked according to conventional critical p value:
p < 0.05.
3. Results
3.1. Number of neurons in CA1, CA2, CA3, and DG
According to the results from physical dissection method
using the formula to find the mean number, the number
of the neurons belongs to all of the hippocampus
regions decreased when we compared the control
group with Alzheimer group and Alzheimer group with
Alzheimer+Tacrolimus group (p < 0.01). There were no
significant differences when comparing Alzheimer with
Alzheimer+Tacrolimus group with each other at any part
of the hippocampus region (p > 0.05). The most dramatic
neuronal decrease was seen at region CA2 and DG in
Alzheimer group when it was compared with control
group (p < 0.01). Interestingly, we found neuronal increase
at Alzheimer+Tacrolimus group for the DG region when
comparing with Alzheimer group (p > 0.05). Also, there
was a neuronal increase in region CA1 and CA3 for
Alzheimer+Tacrolimus group when comparing with
Alzheimer group, but it was not statistically significant (p
> 0.05) (Figure 2).
3.2. Output of the MWM test
MWM test results corresponded to the neuronal loss
outputs. The control group had shown successful
performance at swimming to find the hidden platform,
which was hidden with powder inside the pool
filled with tap water; however, the Alzheimer and
Alzheimer+Tacrolimus groups were not successful as the
control group according to their probe test results (p <
0.01) (Figure 3).
3.3. Expression of c-Fos in the DG
In this study, we hypothesized that tacrolimus might
ameliorate Alzheimer-derived spatial learning and
memory impairments by enhancing hippocampal c-Fos
expression. To evaluate this hypothesis, we immunestained for c-Fos and counted the number of c-Fospositive DG cells. The numbers of c-Fos-positive cells in
the DG were 30.74 ± 5.39 for the control group (Figure
4a), 163.37 ± 2.49 for the Alzheimer group (Figure 4b)
and finally 130.48 ± 10.4 for the Alzheimer+Tacrolimus
group (Figure 4c). We observed a significant increase in
the number of c-Fos-positive cells in Alzheimer group
when comparing with Alzheimer+Tacrolimus group (p <
0.001) (Figure 4).
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Figure 2. This figure is a sum of the tables of four different hippocampal regions for the mean numbers of neurons (±SEM). The
tables show the mean numbers of the neurons from the hippocampus regions. There is a significant difference for CA1, CA3 and
DG regions between control and Alzheimer group (*p < 0.01). There is no significant difference when comparing Alzheimer with
Alzheimer+Tacrolimus group with each other at any part of the hippocampus region (p > 0.05).

4. Discussion
AD is an age related progressive neurodegenerative disease
that is associated with neurobehavioral deterioration and
is characterized by dementia and the loss of neuronal cells
in the brain. Diminished cerebral energy metabolism
results with the accumulation of Aβ peptide that is
related with progressive neuronal degeneration and
death of neurons in several brain regions especially in
hippocampus. Damage in hippocampus area is widely
shown to be related with memory functioning as well as
spatial and contextual learning ability [25]. The presence
of Aβ accumulation or tau neurofibrillary lesions in AD
is less important when compared to neuronal loss. It is
accepted that the dementia in AD is mainly correlated
with neuronal loss [26]. In the light of this information,
we performed a stereological evaluation, which gives us
qualitative information about the mean neuron number
of the hippocampal regions. Our results showed that
significantly neuronal loss was observed especially in

CA1 and CA3 regions in STZ injected groups. However,
there was no significant difference between Alzheimer and
Alzheimer+Tacrolimus groups. Our opinion is that the
dose of the drug we used was insufficient or the application
period was not enough to maintain the effect of the active
ingredient. We proffer different doses of tacrolimus and
prolonged period for new researches. Stereological results
of the CA2 region revealed significant difference between
control and Alzheimer+Tacrolimus groups. Although the
STZ injection significantly decreased the mean neuron
number in CA2 region, besides, there was no difference
between the STZ injected groups. This is probably due
to the fact that the loss of neurons in the CA2 region is
because of negligible size. Similar to our result, Padurariu
et al. [27] investigated the neuronal loss in CA2 region
and they did not find any significant difference. Outcomes
from our MWM test confirmed the decreased number
values of the neurons in the hippocampus regions. The
finding of the hidden platform took longer for the STZ
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Figure 3. Mean values of the MWM test results are shown in the graphic (±SEM). There is a significant difference between control
and Alzheimer group (*p < 0.01) and a significant difference between Alzheimer and Alzheimer+Tacrolimus group (&p < 0.01) when
comparing for pre-test 0; a significant difference between control and Alzheimer group for both pre-test 1 and pre-test 2 (*p < 0.01) is
also present. For probe test, there is a significant difference between control and Alzheimer group (*p < 0.01) and between Alzheimer
and Alzheimer+Tacrolimus group (&p <0.01).

injected animals. There was a significant difference when
comparing control and Alzheimer groups with each other.
This finding is accordance to the hypothesis that IVC
injection of STZ causes neuronal decrease and this leads
damage to the spatial memory. There are several studies
using MWM test for evaluating the impairment of spatial
memory. For example, Bu and Zu [28] have shown the
effects of β-amyloid on memory functions by using MWM
test. According to their data the escape latency among
the control and the treated groups showed significant
differences. C-Fos is an immediate early gene that its
expression is used as a marker for changes in metabolic
activity of neurons. It’s up-regulation in the hippocampus
is known to be related with increased spatial memorial
activity [29]. We observed a significant increase in the
number of c-Fos-positive cells in DG region for Alzheimer
group when compared to the Alzheimer+Tacrolimus
group. This result supports the outcome from the DG
region results from the stereology method for Alzheimer
and Alzheimer+Tacrolimus groups. So, we think that,
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due to the cell proliferation and differentiation, there was
a neuronal activity at the Alzheimer+Tacrolimus group
which was led by tacrolimus, which is a great advancement
for our hypothesis. In fact, the expression of the c-Fos
in the hippocampus was positively correlated to the
spatial recognition score obtained from the MWM test.
Consequently, AD led to increase in expression of c-Fos
in the DG and that possible treatment with tacrolimus
resulted in the alteration of the expression of c-Fos. C-Fos
expression following brain injuries has been considered
related with regeneration level of the neurons. Similar
to the methods in our study, Tsai et. al. [30] applied the
MWM test to examine the results of the c-Fos expression
in rat brains after a transient focal ischemia as memory
impairment is a result of a brain ischemia. Else, Beauquis et
al. [31] used a transgenic PDAPP-J20 mouse animal model
for AD. They observed that without any amyloid plaques
were present and low cerebral levels of amyloid peptides
were detectable, there were structural, morphological, and
cellular alterations in the hippocampus. In addition, their
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Figure 4. Effects of tacrolimus treatment on c-Fos expression in the DG. The graph indicates
the mean number of c-Fos-positive cells in the DG (**p < 0.01); the data are represented as the
mean ± SEM. The photomicrographs demonstrate c-Fos-positive cells in DG regions of control
(a), Alzheimer (b) and Alzheimer+Tacrolimus (c) group. Scale bar represents 50 μm.

reports suggest that the transgenic group showed a high
number of c-Fos-positive nuclei in central and basolateral
amygdala.
5. Conclusion
We demonstrate that an ICV injection of STZ (3 mg/
kg) on the right brain hemisphere leads rats to be an AD
model suffering from neuronal loss, decrease in neuronal
activity and spatial memory impairment (p < 0.01; Oneway ANOVA). ICV injection of the STZ leads apoptosis
and necrosis in the hippocampal brain regions CA1, CA2,
and CA3. We tested the probable protecting effects of
tacrolimus, which was given orally before the STZ injection
on hippocampus. The STZ injection caused significant

neuronal loss in hippocampal regions. However, we found
that c-Fos expression was decreased in the hippocampus
after tacrolimus application, suggesting that tacrolimus
may have had reducing the negative effect of STZ injection
that leads to cellular stress and cell damage. However,
our opinion is that the dosage was not enough to inhibit
the effects of STZ on the CA1, CA2, and CA3 regions of
hippocampus.
Based on these results tacrolimus may be an effective
agent on cell proliferation in experimental Alzheimer
disease model. In order to a new study, for the propose of
the prevention of the neuronal loss in CA1, CA2, CA3 the
dosage or/and the application time of tacrolimus may be
renewable.
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